Cucurbitacin D impedes gastric cancer cell survival via activation of the iNOS/NO and inhibition of the Akt signalling pathway

Zhang,Yan  Zhen; Wang,Chun  Feng; Zhang,Lian  Feng

doi:10.3892/or.2018.6361

Cucurbitacin D impedes gastric cancer cell survival via activation of the iNOS/NO and inhibition of the Akt signalling pathway

Authors:
- Yan Zhen Zhang
- Chun Feng Wang
- Lian Feng Zhang
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: April 10, 2018 https://doi.org/10.3892/or.2018.6361
Pages: 2595-2603
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cucurbitacin D (CuD), isolated from plants from the Cucurbitaceae family, is a potential antitumour agent since it inhibits proliferation, migration and metastasis of cancer cells. Despite CuD antitumour activity in cancer cells, the effects of CuD on gastric cancer cell lines remain unclear. The present study aimed to investigate the effects of CuD on gastric cancer cell growth and death. Human gastric cancer cell lines (AGS, SNU1 and Hs746T) were cultured and treated with different concentrations of CuD (0, 0.25, 0.5, 1 and 2 µM). Cell proliferation was assessed using Cell Counting Kit‑8 assay. Oxidative stress was evaluated by generation of reactive oxygen species (ROS). Cell apoptosis was assessed by terminal deoxynucleotidyl transferase 2'‑deoxyuridine‑5'‑triphosphate nick‑end labelling (TUNEL) staining. Levels of intracellular Ca2+ and adenosine triphosphate (ATP) were also assessed. In the present study, CuD effectively inhibited cell proliferation, triggered ROS generation and induced apoptosis in gastric cancer cells (AGS, SNU1 and Hs746T). Treatment with CuD increased intracellular Ca2+ and ATP levels. CuD also stimulated the expression of inducible nitric oxide synthase (iNOS), which augmented nitric oxide production. In addition, CuD activated the mitochondrial apoptosis pathway, which increased the expression of Bax and the release of cleaved caspace‑9 (C‑caspase‑9) and cytochrome c, decreased the expression of B‑cell lymphoma 2 (Bcl‑2). The mechanism of action of CuD involved the regulation of the protein kinase B/mechanistic target of rapamycin (Akt/mTOR) pathway. We confirmed the effects of CuD on gastric tumours via an in vivo xenograft gastric tumour model. In conclusion, CuD inhibited Akt and activated the iNOS pathway, leading to higher ROS and nitric oxide production, which accelerated gastric cancer cell apoptosis.

View Figures

View References

1	Takahashi T, Saikawa Y and Kitagawa Y: Gastric cancer: Current status of diagnosis and treatment. Cancers. 5:48–63. 2013. View Article : Google Scholar : PubMed/NCBI
2	Patel TN, Roy S and Ravi R: Gastric cancer and related epigenetic alterations. Ecancermedicalscience. 11:7142017. View Article : Google Scholar : PubMed/NCBI
3	Gastric Cancer Treatment (PDQ^®): Health Professional VersionPDQ Cancer Information Summaries. Bethesda, MD: 2002
4	Hu B, El Hajj N, Sittler S, Lammert N, Barnes R and Meloni-Ehrig A: Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol. 3:251–261. 2012.PubMed/NCBI
5	Sikander M, Hafeez BB, Malik S, Alsayari A, Halaweish FT, Yallapu MM, Chauhan SC and Jaggi M: Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer. Sci Rep. 6:365942016. View Article : Google Scholar : PubMed/NCBI
6	Wang Y, Sun Y, Wu Y and Zhang J: Cucurbitacin E inhibits osteosarcoma cells proliferation and invasion through attenuation of PI3K/AKT/mTOR signaling. Biosci Rep. Sep 21–2016.(Epub ahead of print). View Article : Google Scholar
7	Nakanishi T, Song Y, He C, Wang D, Morita K, Tsukada J, Kanazawa T and Yoshida Y: Autophagy is associated with cucurbitacin D-induced apoptosis in human T cell leukemia cells. Med Oncol. 33:302016. View Article : Google Scholar : PubMed/NCBI
8	Ku JM, Kim SR, Hong SH, Choi HS, Seo HS, Shin YC and Ko SG: Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells. Mol Cell Biochem. 409:33–43. 2015. View Article : Google Scholar : PubMed/NCBI
9	Hall JA, Seedarala S, Rice N, Kopel L, Halaweish F and Blagg BS: Cucurbitacin D is a disruptor of the HSP90 chaperone machinery. J Nat Prod. 78:873–879. 2015. View Article : Google Scholar : PubMed/NCBI
10	Hudler P: Challenges of deciphering gastric cancer heterogeneity. World J Gastroenterol. 21:10510–10527. 2015. View Article : Google Scholar : PubMed/NCBI
11	Tran P, Nguyen C and Klempner SJ: Targeting the Phosphatidylinositol-3-kinase pathway in gastric cancer: Can omics improve outcomes? Int Neurourol J. 20 Suppl 2:S131–S140. 2016. View Article : Google Scholar : PubMed/NCBI
12	Fang WL, Huang KH, Lan YT, Lin CH, Chang SC, Chen MH, Chao Y, Lin WC, Lo SS, Li AF, et al: Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers. Oncotarget. 7:6201–6220. 2016. View Article : Google Scholar : PubMed/NCBI
13	Spear SA, Burns SS, Oblinger JL, Ren Y, Pan L, Kinghorn AD, Welling DB and Chang LS: Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: Cucurbitacin D and goyazensolide. Otol Neurotol. 34:1519–1527. 2013. View Article : Google Scholar : PubMed/NCBI
14	Cheng XJ, Lin JC and Tu SP: Etiology and prevention of gastric cancer. Gastrointest Tumors. 3:25–36. 2016. View Article : Google Scholar : PubMed/NCBI
15	Lui VW, Yau DM, Wong EY, Ng YK, Lau CP, Ho Y, Chan JP, Hong B, Ho K, Cheung CS, et al: Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis. 30:2085–2094. 2009. View Article : Google Scholar : PubMed/NCBI
16	Marengo B, Nitti M, Furfaro AL, Colla R, Ciucis CD, Marinari UM, Pronzato MA, Traverso N and Domenicotti C: Redox homeostasis and cellular antioxidant systems: Crucial players in cancer growth and therapy. Oxid Med Cell Longev. 2016:62356412016. View Article : Google Scholar : PubMed/NCBI
17	Morry J, Ngamcherdtrakul W and Yantasee W: Oxidative stress in cancer and fibrosis: Opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles. Redox Biol. 11:240–253. 2017. View Article : Google Scholar : PubMed/NCBI
18	Xu W, Yang Z and Lu N: Molecular targeted therapy for the treatment of gastric cancer. J Exp Clin Cancer Res. 35:12016. View Article : Google Scholar : PubMed/NCBI
19	Ma G, Luo W, Lu J, Ma DL, Leung CH, Wang Y and Chen X: Cucurbitacin E induces caspase-dependent apoptosis and protective autophagy mediated by ROS in lung cancer cells. Chem Biol Interact. 253:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
20	Ishii T, Kira N, Yoshida T and Narahara H: Cucurbitacin D induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial and ovarian cancer cells. Tumour Biol. 34:285–291. 2013. View Article : Google Scholar : PubMed/NCBI
21	Chen LD, Liu ZH, Zhang LF, Yao JN and Wang CF: Sanggenon C induces apoptosis of colon cancer cells via inhibition of No production, iNOS expression and ROS activation of the mitochondrial pathway. Oncol Rep. 38:2123–2131. 2017. View Article : Google Scholar : PubMed/NCBI
22	Vannini F, Kashfi K and Nath N: The dual role of iNOS in cancer. Redox Biol. 6:334–343. 2015. View Article : Google Scholar : PubMed/NCBI
23	Sasaki T and Kuniyasu H: Significance of AKT in gastric cancer (Review). Int J Oncol. 45:2187–2192. 2014. View Article : Google Scholar : PubMed/NCBI
24	Almhanna K, Strosberg J and Malafa M: Targeting AKT protein kinase in gastric cancer. Anticancer Res. 31:4387–4392. 2011.PubMed/NCBI